Medovate, a UK medical device development company based in Cambridge, announced that it has been awarded a new group purchasing agreement with Premier for its regional anaesthesia system SAFIRA (SAFer Injection for Regional Anaesthesia).
Tracy Eke
Image for Premier GPO PR UK version November 2022 - 1
Premier is a healthcare improvement company uniting an alliance of approximately 4,400 U.S. hospitals and health systems and more than 250,000 other providers and organisations. Through approximately 3,000+ negotiated contracts with leading manufacturers, Premier provides its members with access to a contract portfolio to enable them to make savings on medical products.
Effective 1st November 2022, the contract allows members of Premier to be able to purchase at their discretion the SAFIRA system through the special pricing and terms pre-negotiated by Premier in the category of Regional Anaesthesia Trays and Supplies.
Chris Rogers, sales & marketing director at Medovate said: “We are excited to announce that our SAFIRA system is now available through one of the largest national GPO programmes in the US. This is really positive news for Medovate as it helps streamline the purchase of SAFIRA for healthcare organisations delivering services and treatments which use regional anaesthesia, such as ambulatory care and surgical centres. It is a great opportunity to increase the availability of our game-changing technology to regional anaesthesia practitioners in the US to help improve patient safety during peripheral nerve blocks.”
The current regional anaesthesia procedure typically requires an assistant to inject the anaesthetic whilst the anaesthetist uses ultrasound guidance to place the needle. SAFIRA is a technology, developed alongside specialist anaesthesia clinicians in the NHS, designed to reduce the risk of nerve injury during regional anaesthesia.
The SAFIRA system automatically limits injection pressure to a specified threshold to help reduce the risk of nerve injury and improve patient safety. In addition, SAFIRA transforms regional anaesthesia into a one-person procedure by enabling anaesthetists to conduct the entire nerve block process.
Making regional anaesthesia a single-operator procedure further supports the effective application of resources by enabling the clinician to take full control of the injection process, removing the need for a second operator, freeing up nursing staff to carry out other critical tasks.